SHAZ · Investment summary · as of 4 August 2026
Priced for an operating path the record does not support
Business type: venture-like, not yet economically observable
The business does not meet the quality standard for its economic type.
At $52.37, the gap between what the price requires and what the business has demonstrated is -27.5 percentage points.
The conditions that would settle the disagreement are dated to March 2027.
The value rests on an exit multiple of 9.3x and a 11.5% cost of capital. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.
The strongest argument against this view: Committed capacity and committed capital ahead of contractually-floored demand.
| Question | Evidence-based conclusion |
|---|---|
| What drives the business? | Filed XBRL (FY2025 10-K acc 0001493152-26-014068; Q1 2026 10-Q acc 0001493152-26-023769) plus S-1 filed 31 July 2026 (acc 0001493152-26-035629) and eleven 8-Ks 14 May 2026 to 4 August 2026. |
| What do we forecast? | An exit multiple of 9.3x. |
| What does Street forecast? | Not determined — no consensus estimates are joined to this record |
| Where do we differ? | On terminal margin, the difference between what the price requires and what the business has demonstrated is -27.5 percentage points. |
| What is it worth? | Not determined — SANITY BAND, reported as a check and never as a calibration target: the 17 June 2026 institutional private placement priced at $68.73/share ($900m, anchored by Situational… |
| Why now? | The first dated test of the thesis falls on 14 November 2026. |
| Date or window | Event | Thesis confirmed if | Thesis weakened or refuted if |
|---|---|---|---|
| 14 November 2026 | Q3 2026 revenue | Neither leg of the condition opposite is met at this date | The $950m contract does not produce revenue on its own stated schedule (management: 'revenue expected to commence by… |
| Q3 2026 10-Q and FY2026 10-K | Reported gross margin | Neither leg of the condition opposite is met at this date | Unit economics do not invert at scale - cost of revenue exceeded revenue by 79% in the last reported quarter |
| 31 March 2027 | RevenueRemainingPerformanceObligation disclosure | Neither leg of the condition opposite is met at this date | The contracts never become RPO - an enforceable multi-year floor produces a disclosed remaining performance obligation… |
| before the FY2026 10-K | New equity or equity-linked issuance | Neither leg of the condition opposite is met at this date | Equity issuance resumes before revenue does |
Committed capacity and committed capital ahead of contractually-floored demand. Through 2027 SharonAI brings ~132MW of colocation and up to 64,000 GPUs into service as fixed cost, against $2.643bn of announced five-year contract value carrying no disclosed take-or-pay term, no disclosed minimum volume, and no remaining performance obligation in any filing. If those contracts are consumption-based - the ordinary structure for a cloud service agreement, and nothing disclosed contradicts it - utilisation below the announced run-rate lands the fixed cost without the revenue. The $1,050m of converts remain debt at strikes of $48.24 and $99.66; ~$40.3m of annual cash interest accrues against $1.54m of TTM revenue; and the next raise happens into a falling price against 100,000,000 authorised Class A shares over 35,667,164 outstanding.
Estimated probability 45%, against the 12% level at which the position would be resized. It sits above that level, so this case could not be carried at full size.
Falsifiable and fundamental — not one of them is a price condition.
Not determined — no upside discipline is stated, so there is no rule for how this position ends in a favourable outcome
| Criteria | Status | Investment meaning |
|---|---|---|
| Quality | Not met | Is the business worth owning under its declared economic type? |
| Valuation | Not met | Is the operating path required by today's price achievable? |
| Liquidity | Met | Can the intended position be built and exited in the right vehicle? |
| Downside | Met | Committed capacity and committed capital ahead of contractually-floored demand. |
| Momentum | Not determined | Does price action support or complicate entry timing? Not established on the evidence on file. |
| Catalyst | Met | Is there a dated event that resolves the disagreement? |
| Consensus | Not determined | Is the house-versus-Street disagreement identified and quantified? Not established on the evidence on file. |
Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.
The gap between what today's price requires and what the business has demonstrated is -27.5 percentage points, and that gap — not the multiple — is the case that the security is mispriced. The most important unresolved uncertainty is the permanent-loss mechanism: committed capacity and committed capital ahead of contractually-floored demand. The next evidence that should change the portfolio decision is the test dated 14 November 2026, or a daily close below $39.28, which forces an immediate review.